<DOC>
	<DOCNO>NCT00572065</DOCNO>
	<brief_summary>This open-label , one arm , single institution study . Arsenic trioxide [ TrisenoxTM Injection ] , 0.25mg/kg/dose administer intravenously 2 hour . 20 patient Complete remission , partial remission , clinical improvement , progressive disease , stable disease , relapse ( per IWG consensus criterion , 2006 ) Clinical chemistry , hematology ECGs assess least weekly study treatment . Adverse event assess accordance NCI Common Toxicity Criteria , Version 2 study visit .</brief_summary>
	<brief_title>Pilot Trial Arsenic + Cytarabine Patients With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>1 . Patients &gt; = 18 year document history myelofibrosis transform acute myeloid leukemia use World Health Organization criterion &gt; = 20 % blast peripheral blood bone marrow ; diagnosis myelofibrosis could either primary myelofibrosis ( myelofibrosis myeloid metaplasia , agnogenic myeloid metaplasia ) , postpolycythemia vera postessential thrombocytosis . 2 . Patients &gt; = 18 year myelofibrosis ( either primary ( myelofibrosis myeloid metaplasia , agnogenic myeloid metaplasia ) , post polycythemia vera post essential thrombocytosis ) 1 ) meet Mayo Clinic criterion high risk disease ( &gt; = 2 follow criterion : hemoglobin &lt; 10 g/dL , WBC &lt; 4 &gt; 30 x 109/L , platelet &lt; 100 x 109/L , absolute monocyte count &gt; = 1 x 109/L ) AND 2 ) fail respond treatment least one prior therapy myelofibrosis ( erythropoietic cytokine , androgen , hydrea , interferon , thalidomide , lenalidomide investigational therapy ) . 3 . Patients must discontinue prior myelofibrosis treatment ( exception hydrea , permit control leukocytosis ) least 14 day prior start study drug 4 . ECOG performance status &lt; = 2 5 . Serum creatinine &lt; = 2.5 time upper limit normal 6 . Serum bilirubin &lt; = 2.5 time upper limit normal 7 . Serum potassium &gt; 4.0 mEq/dL serum magnesium &gt; 2.0 mg/dL . If serum electrolyte specify limit baseline laboratory test , electrolyte administer bring serum concentration level administer arsenic trioxide . 8 . Patients eligible trial regardless gender , racial/ethnic background , provide inclusion exclusion criterion meet patient patient 's legally authorize guardian sign inform consent . 1 . Pregnant lactate woman 2 . Presence ( 9 ; 22 ) translocation cytogenetically , presence bcrabl FISH ( fluorescence situ hybridization ) PCR ( polymerase chain reaction ) 3 . Absolute QT interval &gt; 500 msec presence serum potassium â‰¥ 4.0 mEq/L magnesium &gt; = 1.8 mg/dL . 4 . Prior cytotoxic chemotherapy AML MDS ; prior treatment hydroxyurea , 5azacytidine , decitabine , thalidomide lenalidomide permit . Prior treatment lowdose cytarabine permit . 5 . Concurrent treatment maintenance therapy , cytotoxic chemotherapy , radiation , investigational agent . 6 . Uncontrolled severe cardiovascular , pulmonary infectious disease medical condition would prohibit use plan study treatment . 7 . Inability unwillingness comply treatment protocol , followup , research test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>